Your Location：
Home >
Browse articles >
Effect of Gegen Tongmaiyin on Preventing Atherosclerosis by Down-regulating BIP Protein Expression
Updated：2024-01-04
Previous|Next

    • Effect of Gegen Tongmaiyin on Preventing Atherosclerosis by Down-regulating BIP Protein Expression

    • HU Hai-tao , XU Xue-qin , SHEN Xiao-jun
    • Chinese Journal of Experimental Traditional Medical Formulae Vol. 21, Issue 1, Pages: 150-153(2015)

    • DOI： 10.13422/j.cnki.syfjx.2015010150     

      CLC：

    Scan QR Code

  •  
  •  

  • Full Text(HTML)

  • References

  • Publication Info

  • Metrics

Sections
icon
The trial reading is over, you can activate your VIP account to continue reading.
Deactivate >
icon
The trial reading is over. You can log in to your account, go to the personal center, purchase VIP membership, and read the full text.
Already a VIP member?
Log in >

53

Views

39

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Clinical Research of How Gegen Tongmaiyin Downregulating Plasma NF-B to Prevent Atherosclerosis
Mechanism of Wendan Tang Against Atherosclerosis by Regulating Ferroptosis Based on JAK2/STAT3 Signaling Pathway
Iron Homeostasis Imbalance Promotes Atherosclerosis and Therapeutic Mechanisms of Traditional Chinese Medicine
Mechanism of Huoxin Pills in Stabilizing Atherosclerotic Vulnerable Plaque Based on Network Pharmacology and Metabolomics
Differentiation and Treatment of Vulnerable Atherosclerotic Plaque Based on "Collateral Disease" Theory

Related Author

ZHANG Yan
SUN Jie
WANG Tan
QIU Tingting
OUYANG Xiaoqiang
FANG Bangjiang
WANG Maohong
XIONG Jianhua

Related Institution

Jiangxi University of Chinese Medicine
The Affiliated Hospital of Jiangxi University of Chinese Medicine
Longhua Hospital Shanghai University of Traditional Chinese Medicine
School of Chinese Materia Medica，Guangzhou University of Chinese Medicine
Baiyunshan Pharmaceutical General Factory， Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.